[HTML][HTML] Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes
T John, A Taylor, H Wang, C Eichinger, C Freeman… - Cancer …, 2022 - Elsevier
Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …
[HTML][HTML] Correlation between EGFR mutation status and the incidence of brain metastases in patients with non-small cell lung cancer
L Li, S Luo, H Lin, H Yang, H Chen, Z Liao… - Journal of thoracic …, 2017 - ncbi.nlm.nih.gov
Background Lung cancer is the leading cause of cancer-related death worldwide. Numerous
studies have been performed to investigate the correlation between epidermal growth factor …
studies have been performed to investigate the correlation between epidermal growth factor …
[HTML][HTML] ErbB family signalling: a paradigm for oncogene addiction and personalized oncology
N Jacobi, R Seeboeck, E Hofmann, A Eger - Cancers, 2017 - mdpi.com
ErbB family members represent important biomarkers and drug targets for modern precision
therapy. They have gained considerable importance as paradigms for oncoprotein addiction …
therapy. They have gained considerable importance as paradigms for oncoprotein addiction …
[HTML][HTML] Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study
HY Yoon, JS Ryu, YS Sim, D Kim, SY Lee, J Choi… - PLoS …, 2020 - journals.plos.org
Adenocarcinoma is the most common type of non-small cell lung cancer. Some causative
genomic alterations in epidermal growth factor receptor (EGFR), including deletions in exon …
genomic alterations in epidermal growth factor receptor (EGFR), including deletions in exon …
[HTML][HTML] EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer
P Tomasini, C Serdjebi, N Khobta, P Metellus… - International journal of …, 2016 - mdpi.com
Background: Lung cancer is the leading cause of brain metastases (BM). The identification
of driver oncogenes and matched targeted therapies has improved outcome in non-small …
of driver oncogenes and matched targeted therapies has improved outcome in non-small …
[HTML][HTML] Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatment
JL Kuiper, SMS Hashemi, E Thunnissen… - British journal of …, 2016 - nature.com
Background: Data on non-small-cell lung cancer (NSCLC) patients with non-classic
epidermal growth factor receptor (EGFR) mutations are scarce, especially in non-Asian …
epidermal growth factor receptor (EGFR) mutations are scarce, especially in non-Asian …
[HTML][HTML] EGFR variant allele frequency predicts EGFR-TKI efficacy in lung adenocarcinoma: a multicenter study
B Gieszer, Z Megyesfalvi, V Dulai, J Papay… - Translational Lung …, 2021 - ncbi.nlm.nih.gov
Background Although lung adenocarcinoma (LADC) with sensitizing mutations of the
epidermal growth factor receptor (EGFR) is highly sensitive to EGFR tyrosine kinase …
epidermal growth factor receptor (EGFR) is highly sensitive to EGFR tyrosine kinase …
Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma
LX Feng, J Wang, Z Yu, SA Song, WX Zhai… - Clinical and …, 2019 - Springer
Objective To study the clinical significance of serum epidermal growth factor receptor
(EGFR) gene mutation and serum tumor markers in the prediction of tyrosine kinase inhibitor …
(EGFR) gene mutation and serum tumor markers in the prediction of tyrosine kinase inhibitor …
[HTML][HTML] The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer
S Al-Saad, E Richardsen, TK Kilvaer, T Donnem… - PloS one, 2017 - journals.plos.org
Introduction To compare the efficacy of silver in situ hybridization (SISH) and
immunohistochemistry (IHC) in detecting MET and IGF1R alterations and to investigate their …
immunohistochemistry (IHC) in detecting MET and IGF1R alterations and to investigate their …
Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
Z Zhang, K Zeng, S Zhao, Y Zhao… - Therapeutic …, 2019 - journals.sagepub.com
Background: First-line treatments for nonsmall cell lung cancer (NSCLC) harboring
epidermal growth factor receptor (EGFR) mutations have been evaluated in various clinical …
epidermal growth factor receptor (EGFR) mutations have been evaluated in various clinical …